You are here
Yoshiya Tanaka, MD, PhD
Yoshiya Tanaka, MD, PhD, has been a professor and the Chairman of the First Department of Internal Medicine, School of Medicine at the University of Occupational and Environmental Health in Japan since 2000. He was a visiting fellow from 1989 to 1992 in the Experimental Immunology Branch at the National Cancer Institute, National Institutes of Health in the United States. Dr Tanaka has authored and reviewed 461 publications in English, and his research focus lies in the pathological analysis and development of novel treatment of patients with systemic autoimmune diseases, rheumatic diseases, and endocrine metabolic diseases, including osteoporosis. He was the president of the Japanese Society of Bone and Mineral Research from 2013 to 2015, a council and editorial member of Japanese Society of Internal Medicine, and a board member for the Japanese College of Rheumatology, the Japanese Association of Clinical Immunology, and the Japanese Society of Inflammation and Regeneration. He is also an associate editor of Rheumatology, the editor-in-chief of Modern Rheumatology Case Reports, an editorial board member of Annals of Rheumatic Diseases, RMD Open, Modern Rheumatology, Inflammation Research, and numerous others. He has received numerous awards from the Japanese Society of Inflammation, the Japanese Society of Bone and Mineral Research, the Japanese College of Rheumatology, and the European League Against Rheumatism for his work.
Grant/Research Support: AbbVie Inc.; Astellas Pharma Inc.; Bristol-Myers Squibb Company; Chugai Pharmaceutical Co., Ltd; Daiichi Sankyo Company, Limited; Eisai Co., Ltd.; Mitsubishi Tanabe Pharma Corporation; MSD & Co., Inc.; Takeda Pharmaceutical Company Limited
Speakers’ Bureau: AbbVie Inc.; Asahi Kasei Corporation; Astellas Pharma Inc.; Bristol-Myers Squibb Company; Chugai Pharmaceutical Co., Ltd; Daiichi Sankyo Company, Limited; Eli Lilly and Company; GlaxoSmithKline plc.; Janssen Global Services, LLC; Mitsubishi Tanabe Pharma Corporation; Pfizer Inc.; Sanofi; Takeda Pharmaceutical Company Limited; Teijin Pharma Limited; YL Biologics